指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

布地奈德雾化吸入治疗成人哮喘与慢阻肺的德尔菲共识

A Delphi consensus on nebulized budesonide for adults with asthma and COPD.
指南 / 共识 · Asian Pac J Allergy Immunol · 2026-01-01
一句话结论泰国13名呼吸专家德尔菲共识:雾化布地奈德是成人哮喘和慢阻肺有效且耐受良好的治疗选择,重症急性发作时雾化给药比压力定量吸入器加储雾罐更合适。

该德尔菲共识由泰国13名呼吸科医师(肺科9名、过敏科1名、急诊科顾问3名)组成专家组,采用5点李克特量表对雾化吸入糖皮质激素(如布地奈德)在成人哮喘和慢阻肺急性和维持治疗中的使用进行共识评分。共形成12条共识声明,总体共识度很高(平均同意评分4.2-4.9/5)。专家组对以下两条声明共识最强(84.6%强烈同意):吸入装置是哮喘和慢阻肺患者药物递送的基石;对于成人哮喘和慢阻肺重症急性发作,雾化给药比压力定量吸入器加储雾罐更合适。结论认为雾化布地奈德是成人哮喘和慢阻肺有效且耐受良好的治疗选择。

要点

  • 专家组84.6%强烈同意:吸入装置是哮喘和慢阻肺患者药物递送的基石。
  • 专家组84.6%强烈同意:成人哮喘和慢阻肺重症急性发作时,雾化给药比压力定量吸入器加储雾罐更合适。
  • 12条共识声明覆盖成人哮喘和慢阻肺的急性期与维持治疗,平均同意评分4.2-4.9/5。
  • 共识认为雾化布地奈德是成人哮喘和慢阻肺有效且耐受良好的治疗选择。

适用人群与场景

  • 成人哮喘和慢阻肺患者,涵盖急性期与维持治疗场景。

处置流程与药物剂量

  • 对于成人哮喘和慢阻肺重症急性发作,专家组认为雾化给药比压力定量吸入器加储雾罐更合适(84.6%强烈同意)。
  • 吸入装置是哮喘和慢阻肺患者药物递送的基石(84.6%强烈同意)。

研究设计与关键结果

  • 制定机构为泰国三级医疗中心的13名呼吸科医师专家组(肺科9名、过敏科1名、急诊科顾问3名),采用德尔菲法,以5点李克特量表评分。
  • 共形成12条关于雾化吸入糖皮质激素(如布地奈德)用于成人哮喘和慢阻肺急性与维持治疗的共识声明。
  • 12条声明的总体共识度很高,平均同意评分4.2-4.9/5。
  • 共识最强的两条声明获84.6%强烈同意:吸入装置是药物递送的基石;重症急性发作时雾化给药比压力定量吸入器加储雾罐更合适。

证据类型、等级与局限

  • 证据类型:德尔菲共识(专家意见)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为雾化布地奈德是成人哮喘和慢阻肺有效且耐受良好的治疗选择。
  • 对于成人哮喘和慢阻肺重症急性发作,专家组认为雾化给药比压力定量吸入器加储雾罐更合适(84.6%强烈同意)。

指南或共识出处

  • 布地奈德雾化吸入治疗成人哮喘与慢阻肺的德尔菲共识(Asian Pac J Allergy Immunol)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Inhaled corticosteroids (ICS) represent an alternative treatment option to systemic corticosteroids (SCS) in the treatment of asthma and chronic obstructive pulmonary disease (COPD); however, detailed clinical guidance on the use of nebulized ICS, such as budesonide, in the management of asthma and COPD remains scarce.

OBJECTIVE: To review the literature and develop Delphi consensus statements on the use of nebulized ICS for the management of asthma and COPD in adults.

METHODS: An expert panel of 13 respiratory physicians, comprising pulmonologists (n = 9), allergists (n = 1), and emergency department consultants (n = 3) from tertiary medical centers in Thailand, undertook a Delphi procedure with the aim of developing evidence-based consensus statements on the use of nebulized ICS in patients with asthma and COPD. Panelists used a 5-point Likert scale to score their agreement with each statement.

RESULTS: A total of 12 Delphi consensus statements pertaining to the use of nebulized ICS in the management of asthma and COPD in both acute and maintenance care were developed. The overall consensus of the panel across the 12 statements was very high (mean agreement score, 4.2-4.9/5). The panelists expressed strongest consensus agreement (84.6% strong agreement) with the following two statements: 1) inhalation devices are the cornerstone of drug delivery in patients with asthma and COPD, and 2) for adult asthma and COPD patients with severe exacerbations, nebulization is more suitable for drug delivery than a pMDI plus spacer.

CONCLUSIONS: Nebulized budesonide is an effective and well tolerated treatment option for the management of asthma and COPD.

来源:Asian Pac J Allergy Immunol,查看原文。版权归原作者所有。

参考来源

  1. Wongsurakiat P, Rattanawongpaibul A, Limsukon A, et al. A Delphi consensus on nebulized budesonide for adults with asthma and COPD. Asian Pac J Allergy Immunol. 2026. PMID: 40459870. doi:10.12932/AP-190824-1910

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。